Ritholtz Wealth Management Sells 176 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Ritholtz Wealth Management reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 11.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,313 shares of the medical research company’s stock after selling 176 shares during the period. Ritholtz Wealth Management’s holdings in Bio-Rad Laboratories were worth $750,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Profund Advisors LLC grew its stake in shares of Bio-Rad Laboratories by 3.3% in the 4th quarter. Profund Advisors LLC now owns 504 shares of the medical research company’s stock worth $294,000 after buying an additional 16 shares in the last quarter. Csenge Advisory Group grew its stake in shares of Bio-Rad Laboratories by 3.9% in the 1st quarter. Csenge Advisory Group now owns 457 shares of the medical research company’s stock worth $275,000 after buying an additional 17 shares in the last quarter. Greenleaf Trust grew its stake in shares of Bio-Rad Laboratories by 5.2% in the 1st quarter. Greenleaf Trust now owns 406 shares of the medical research company’s stock worth $232,000 after buying an additional 20 shares in the last quarter. BBVA USA Bancshares Inc. grew its stake in shares of Bio-Rad Laboratories by 0.6% in the 1st quarter. BBVA USA Bancshares Inc. now owns 3,926 shares of the medical research company’s stock worth $2,242,000 after buying an additional 24 shares in the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Bio-Rad Laboratories by 1.2% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 1,947 shares of the medical research company’s stock worth $1,112,000 after buying an additional 24 shares in the last quarter. Institutional investors own 65.18% of the company’s stock.

BIO stock opened at $602.97 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $425.43 and a 12 month high of $689.00. The business’s 50-day moving average price is $604.41. The stock has a market cap of $17.95 billion, a PE ratio of 4.43 and a beta of 0.83.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings results on Thursday, April 29th. The medical research company reported $5.21 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $2.71. Bio-Rad Laboratories had a net margin of 151.73% and a return on equity of 4.55%. The firm had revenue of $726.80 million during the quarter, compared to analysts’ expectations of $661.00 million. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 12.07 EPS for the current year.

Separately, Citigroup lifted their price objective on shares of Bio-Rad Laboratories from $675.00 to $750.00 and gave the stock a “buy” rating in a research note on Friday, February 12th.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components.

Featured Article: What is Cost of Goods Sold (COGS)?

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.